Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics

Mar 12, 2025•over 1 year ago

Contract Type

partnership

EdmontonBiotechnologyHealth CareTherapeutics

Description

Entos Pharmaceuticals has announced a $198.5 million partnership with the Governments of Canada and Alberta to accelerate the biomanufacturing of Fusogenix PLV next generation therapeutics. The investment will help build an R&D center and a GMP manufacturing facility in Edmonton, Alberta, aiming to foster collaborations between Entos, Canadian academic institutions, and its industry partners.

Company Information

Company

Entos Pharmaceuticals

Location

Edmonton, England, United Kingdom

About

Entos Pharmaceuticals is a clinical-stage genetic medicines company focused on developing cures and improving patients' lives using its proprietary Fusogenix™ PLV™ technology. The company aims to address rare genetic disorders through innovative genetic medicine approaches. Since its founding in 2016, Entos has been committed to advancing next-generation genetic medicines.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Entos Pharmaceuticals's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.